



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/757,551	01/15/2004	Orhun K. Muratoglu	37697-0085	3038

26633 7590 09/22/2005

HELLER EHRMAN WHITE & MCAULIFFE LLP
1717 RHODE ISLAND AVE, NW
WASHINGTON, DC 20036-3001

EXAMINER

STAICOVICI, STEFAN

ART UNIT	PAPER NUMBER
----------	--------------

1732

DATE MAILED: 09/22/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/757,551	Applicant(s) MURATOGLU ET AL.	
	Examiner Stefan Staicovici	Art Unit 1732	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 06 July 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-80 is/are pending in the application.
- 4a) Of the above claim(s) 78 and 79 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-77 and 80 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Response to Amendment

1. Applicants' response filed July 6, 2005 has been entered. Claims 1-80 are pending in the instant application.

Election/Restrictions

2. This application contains claim 78-79 drawn to an invention nonelected with in the response filed March 28, 2005. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 1-2, 5-19, 21-35, 38-42, 45-49, 52-55, 57, 59-62, 64-72 and 77 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lidgren *et al.* (US Patent No. 6,448,315) in view of Hahn (US Patent No. 5,827,904).

Lidgren *et al.* ('315) teach the basic process for making a medical implant including, providing UHMWPE powder, mixing said powder with vitamin E (antioxidant) to reduce oxidation, irradiating said mixture with radiation, compression molding said irradiated mixture

into said medical implant or machining medical implants from compression molded blocks of said irradiated mixture, packaging said medical implant and sterilizing said package (see col. 4, line 45 through col. 5, line 10 and col. 5, line 66 through col. 6, line 8). Further, it is submitted that Lidgren *et al.* ('315) teach reducing the free radicals and irradiating said mixture to cross-link the PE chains, hence controlling the amount of free radicals by irradiation and antioxidant amount.

Regarding claims 1, 34-35, 41-42, 48-49, 55, 62 and 77, although Lidgren *et al.* ('315) teach doping a polymeric material (powder) with an antioxidant (vitamin E), Lidgren *et al.* ('315) do not teach doping a consolidated polymeric material with an antioxidant by diffusion. Hahn ('904) teaches a process for making a medical implant including, consolidating a polymeric material (UHMWPE) and doping said consolidated polymeric material with an antioxidant as an equivalent alternative to doping the polymeric material (see col. 3, lines 15-20 and col. 7, lines 24-47). Further, Hahn ('904) teaches soaking said consolidated polymeric material in an antioxidant solution such that the soaking time, temperature and solution strength determine the doping level (see col. 3, lines 29-35). Therefore, it would have been obvious for one of ordinary skill in the art to have doped a consolidated polymeric material as an equivalent alternative to doping the polymeric material as taught by Hahn ('904) in the process of Lidgren *et al.* ('315) because, Hahn ('904) teaches that such process step sequences are equivalent alternatives and also because both references teach the same polymeric material, UHMWPE, and the same end-product (medical implant).

In regard to claims 5-7, 38-40, 45-47, 52-54, 59-61 and 65-67, Hahn ('904) teaches

soaking said consolidated polymeric material in an antioxidant solution such that the soaking time, temperature and solution strength determine the doping level (see col. 3, lines 29-35). Hence, it is submitted that soaking time, temperature and solution strength are result-effective variables. In re Antonie, 559 F.2d 618, 195 USPQ 6 (CCPA 1977). Therefore, it would have been obvious for one of ordinary skill in the art to have doped a consolidated polymeric material as an equivalent alternative to doping the polymeric material as taught by Hahn ('904) in the process of Lidgren *et al.* ('315) because, Hahn ('904) specifically teaches that such process step sequences are equivalent alternatives and also because both references teach the same polymeric material, UHMWPE, and the same end-product (medical implant).

Specifically regarding claims 8 and 68, Lidgren *et al.* ('315) teach annealing at a temperature above the melting temperature of the consolidated polymeric material (see col. 6, lines 8-18).

Regarding claims 9-10, 12, 30-31, 69-70 and 72, Lidgren *et al.* ('315) teach UHMWPE (polyolefin) powder and an antioxidant (vitamin E, alpha-tocopherol) (see Abstract).

In regard to claims 11 and 71, Lidgren *et al.* ('315) teach a medical implant for a joint replacement, specifically a femoral component (see col. 1, lines 13-16 and 50-55).

Specifically regarding claims 13-19, 21-26, 57 and 64, Lidgren *et al.* ('315) teach gamma radiation of 3.3-100 Mrad in air and an inert atmosphere, *i.e.* nitrogen gas (fluid) and, remelting the irradiated polymer in a non-oxidative atmosphere, *i.e.* inert or vacuum (1% oxygen) to reduce the free radicals (see col. 2, lines 13-55).

Regarding claim 27, Lidgren *et al.* ('315) teach the use of a solvent (ethanol) (see col. 3,

lines 10-15).

In regard to claims 28-29, Lidgren *et al.* ('315) teach diffusion of an antioxidant in a supercritical fluid such as, CO₂ (see col. 4, lines 62-65).

Specifically regarding claims 32-33, it is noted that the limitation are functional limitations. In a claim drawn to a process of making, it is the structure that carries patentability and not the functional limitation. Therefore, it would have been obvious for one of ordinary skill in the art to have made a non-permanent medical device, such as a tubing using the process of Lidgren *et al.* ('315) in view of Hahn ('904) because, Lidgren *et al.* ('315) teaches that the doped UHMWPE provides for improved properties that enhance the material's use a biological material, hence providing for an improved product such as a catheter or a non-permanent medical device.

5. Claim 20 is rejected under 35 U.S.C. 103(a) as being unpatentable over Lidgren *et al.* (US Patent No. 6,448,315) in view of Hahn (US Patent No. 5,827,904) and in further view of Parth *et al.* (2002) (referenced as A11 in the IDS filed 7/16/2004).

Lidgren *et al.* ('315) in view of Hahn ('904) teach the basic claimed process as described above.

Regarding claim 20, although Lidgren *et al.* ('315) in view of Hahn ('904) teach treating UHMWPE with gamma radiation, Lidgren *et al.* ('315) in view of Hahn ('904) do not teach e-beam radiation. However, the use of e-beam radiation as an equivalent alternative to gamma radiation (see Abstract and Conclusions) is well known as evidenced by Parth *et al.* (2002). Therefore, it would have been obvious for one of ordinary skill to have used e-beam radiation as

an equivalent alternative to gamma radiation as taught by Parth *et al.* (2002) to treat UHMWPE in the process of Lidgren *et al.* ('315) in view of Hahn ('904) because, Parth *et al.* (2002) specifically teach the use of e-beam radiation as an equivalent alternative to gamma radiation and also because all references teach similar materials and end-products.

6. Claims 3-4, 36-37, 43-44, 50-51, 56, 58, 63 and 73-75 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lidgren *et al.* (US Patent No. 6,448,315) in view of Hahn (US Patent No. 5,827,904) and in further view of Burstein *et al.* (US Patent No. 6,620,198).

Lidgren *et al.* ('315) in view of Hahn ('904) teach the basic claimed process as described above.

Regarding claims 3-4, 36-37, 43-44, 50-51, 56, 58, 63, 73-75, although Lidgren *et al.* ('315) teach a metallic/UHMWPE component (see col. 1, lines 14-20), Lidgren *et al.* ('315) in view of Hahn ('904) do not teach compression molding a metallic/UHMWPE component. Burstein *et al.* ('198) teach compression molding a polymer element (140) (UHMWPE) and a metallic element (130) to form a medical component (see col. 5, lines 1-10). It is submitted that a metallic/UHMWPE component includes a metal/polymer interface. Therefore, it would have been obvious for one of ordinary skill in the art to have compression molded a polymer element and a metallic element as taught by Burstein *et al.* ('198) to form a medical component by the process of Lidgren *et al.* ('315) because, Burstein *et al.* ('198) teach that a metallic/polymer interface provides for an improved product having improved biological properties and also because Lidgren *et al.* ('315) teach a metallic/UHMWPE component (see col. 1, lines 14-20), hence teaching the desirability of a metallic/polymer interface.

7. Claims 76 and 80 are rejected under 35 U.S.C. 103(a) as being unpatentable over Lidgren *et al.* (US Patent No. 6,448,315) in view of Hahn (US Patent No. 5,827,904) and in further view of Burstein *et al.* (US Patent No. 6,620,198) and Ylanen *et al.* (US Patent No. 6,517,857 B2).

Lidgren *et al.* ('315) in view of Hahn ('904) and in further view of Burstein *et al.* ('198) teach the basic claimed process as described above.

Regarding claims 76 and 80, although Lidgren *et al.* ('315) teach a metallic/UHMWPE component (see col. 1, lines 14-20), Lidgren *et al.* ('315) in view of Hahn ('904) and in further view of Burstein *et al.* ('198) do not teach compression molding a metallic/ceramic component. Ylanen *et al.* ('857) teach that polymers, metals and ceramic are all alternative materials for making a medical component. Therefore, it would have been obvious for one of ordinary skill in the art to have compression molded a ceramic element (non-metallic) and a metallic element to form a ceramic/metallic interface by the process of Lidgren *et al.* ('315) in view of Hahn ('904) and in further view of Burstein *et al.* ('198) and Ylanen *et al.* ('857) because, Ylanen *et al.* ('857) specifically teach that polymers, metals and ceramic are all alternative materials for making a medical component, whereas Lidgren *et al.* ('315) teach a medical component.

Response to Arguments

8. Applicants' remarks filed July 6, 2005 have been considered.

9. Applicants argue that "Lidgren and Hahn neither teach or suggest irradiating UHMWPE to cross-link...prior to doping with an antioxidant in order to improve wear resistance of the UHMWPE." Further, Applicants argue that "cross-linking of consolidated UHMWPE prior to

doping with an antioxidant, is not taught or suggested by Lidgren or Hahn” (see page 13 of the amendment filed 7/6/2005). Furthermore, Applicants argue that “Hahn discloses doping of UHMWPE with an antioxidant and is silent on when the doping is carried out, whereas Lidgren carries out doping prior to irradiation,” whereas “ according to the claimed processes, doping is a post-irradiation step” (see page 14 of the amendment filed 7/6/2005). In response, it is noted that:

(a) Lidgren *et al.* ('315) specifically teaches in col. 6, lines 8-15 that the antioxidant doped UHMWPE is subjected to radiation in order to promote cross-linking. Further, it is noted that Lidgren *et al.* ('315) teaches in col. 2, lines 14-18 that it is generally well known to irradiate UHMWPE in order to induce controlled cross-linking. Furthermore, Lidgren *et al.* ('315) teaches that the UHMWPE powder doped with antioxidant is compression molded into blocks (consolidated) and then processed into medical implants from said blocks (see col. 6, lines 1-5).

(b) under §MPEP2144(IV)(C), the “selection of any order of performing process steps is *prima facie* obvious in the absence of new or unexpected results. See, In re Burhans, 154 F.2d 690, 69 USPQ 330 (CCPA 1946). In this case, Hahn ('904) specifically teaches consolidating a polymeric material (UHMWPE) and doping said consolidated polymeric material with an antioxidant as an equivalent alternative to doping the polymeric material prior to its consolidation (see col. 3, lines 15-20 and col. 7, lines 24-47).

Therefore, it would have been obvious for one of ordinary skill in the art to have doped a consolidated polymeric material as an equivalent alternative to doping the polymeric material as taught by Hahn ('904) in the process of Lidgren *et al.* ('315) because, Hahn ('904) teaches that

Art Unit: 1732

such process step sequences are equivalent alternatives and also because both references teach the same polymeric material, UHMWPE, and the same end-product (medical implant).

10. In response to applicant's arguments against the references individually (see page 15 of the amendment filed 7/6/2005), one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986).

11. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.


Conclusion

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Stefan Staicovici, Ph.D. whose telephone number is (571) 272-1208. The examiner can normally be reached on Monday-Friday 9:30 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael P. Colaianni, can be reached on (571) 272-1196. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Stefan Staicovici, PhD



Primary Examiner

9/18/05

AU 1732

September 18, 2005